Home>>Signaling Pathways>> Neuroscience>> mAChR>>Vinconate (Chanodesethylapovinc amine)

Vinconate (Chanodesethylapovinc amine) Sale

(Synonyms: 长春考酯,Chanodesethylapovinc?amine) 目录号 : GC31262

Vinconate (Chanodesethylapovinc amine) 是一种吲哚萘啶衍生物,可刺激毒蕈碱乙酰胆碱受体。

Vinconate (Chanodesethylapovinc amine) Chemical Structure

Cas No.:70704-03-9

规格 价格 库存 购买数量
 1mg
¥5,177.00
现货
 5mg
¥10,264.00
现货
 10mg
¥17,493.00
现货
 20mg
¥30,791.00
现货

电话:400-920-5774 Email: sales@glpbio.cn

Customer Reviews

Based on customer reviews.

Sample solution is provided at 25 µL, 10mM.

产品文档

Quality Control & SDS

View current batch:

实验参考方法

Animal experiment:

344 male rats, 6 months (adult) and 24 months (aged) of age, are allowed food and water ad lib throughout the experiments. Rats are divided into four groups; (1) 6-month-old; (2) vehicle (distilled water) is administered intraperitoneally (i.p.) once a day for 4 weeks before decapitation; (3) Vinconate at a dose of 10 mg/kg is administered i.p. once a day for 4 weeks before decapitation; (4) Vinconate at a dose of 30 mg/kg is administered i.p. once a day for 4 weeks before decapitation. Rats in groups (2) to (4) are 24 months old. Each group contains 6 to 7 rats. In addition, there are no significant differences among the three aged animal groups in body weight after drug or vehicle treatment[2].

References:

[1]. Iino T, et al. Effect of vinconate, an indolonaphthyridine derivative, on dopamine and serotonin concentrations in dialysate from the striatum of freely moving rats: brain microdialysis studies. J Pharmacol Exp Ther. 1996 Aug;278(2):614-9.
[2]. Araki T, et al. Effects of vinconate on neurotransmitter receptor systems in aged rat brain. Environ Toxicol Pharmacol. 1996 Dec 20;2(4):343-9.

产品描述

Vinconate is an indolonaphthyridine derivative and can stimulate the muscariic acetylcholine receptor.

Treatment with Vinconate (50 to 200 mg/kg p.o.) significantly increases dopamine concentrations in dialysate. Daily treatment with Vinconate (25 mg/kg) for 7 days also significantly increases dopamine and serotonin concentrations in dialysate[1]. Chronic treatment with Vinconate at a 10 mg/kg significantly ameliorats the reduction in [3H]QNB binding in the nucleus accumbens and cerebellum. Furthermore, this Vinconate treatment significantly enhances [3H]QNB binding in the frontal cortex and hippocampus compare with the vehicle-treated aged animals. Also, chronic treatment with Vinconate at the higher dose significantly elevates [3H]QNB binding in the hippocampal CA3 sector and dentate gyrus compare with the vehicle-treated aged animals. Chronic treatment with Vinconate at a dose of 10 mg/kg shows a significant reduction in [3H]HC binding only in the hippocampal CA1 sector compare with the vehicle-treated aged rats[2].

[1]. Iino T, et al. Effect of vinconate, an indolonaphthyridine derivative, on dopamine and serotonin concentrations in dialysate from the striatum of freely moving rats: brain microdialysis studies. J Pharmacol Exp Ther. 1996 Aug;278(2):614-9. [2]. Araki T, et al. Effects of vinconate on neurotransmitter receptor systems in aged rat brain. Environ Toxicol Pharmacol. 1996 Dec 20;2(4):343-9.

Chemical Properties

Cas No. 70704-03-9 SDF
别名 长春考酯,Chanodesethylapovinc?amine
Canonical SMILES O=C(C1=CCC2N(CC)CCC3=C2N1C4=C3C=CC=C4)OC
分子式 C18H20N2O2 分子量 296.36
溶解度 Soluble in DMSO 储存条件 Store at -20°C
General tips 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。
为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。
Shipping Condition 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。

溶解性数据

制备储备液
1 mg 5 mg 10 mg
1 mM 3.3743 mL 16.8714 mL 33.7427 mL
5 mM 0.6749 mL 3.3743 mL 6.7485 mL
10 mM 0.3374 mL 1.6871 mL 3.3743 mL
  • 摩尔浓度计算器

  • 稀释计算器

  • 分子量计算器

质量
=
浓度
x
体积
x
分子量
 
 
 
*在配置溶液时,请务必参考产品标签上、MSDS / COA(可在Glpbio的产品页面获得)批次特异的分子量使用本工具。

计算

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % saline
计算重置

Research Update

(+-)-Methyl-2,3,3a,4-tetrahydro-1H-indolo [3,2,1-de] [1,5] naphthyridine-6-carboxylate monohydrochloride facilitates phosphatidylinositol hydrolysis: possible involvement of muscarinic and nonmuscarinic mechanisms

The stimulation of the formation of inositol phosphate (IP) by (+-)-methyl-2,3,3a,4-tetrahydro-1H-indolo [3,2,1-de] [1,5] naphthyridine-6-carboxylate monohydrochloride (vinconate), a novel indolonaphthyridine derivative, was studied using both cerebral cortical slices and crude synaptic membranes prepared from the rat brain. Vinconate (10 mM-1 mM) inhibited the binding of [3H]quinuclidinyl benzilate to the muscarinic receptor in a dose-dependent manner and the IC50 value for [3H]quinuclidinyl benzilate binding was found to be 17 microM. The rightward shift of the inhibition curve of [3H]quinuclidinyl benzilate binding by carbachol in the presence of GTP (100 microM) was abolished by vinconate (100 microM). Carbachol (10 nM-10 mM) significantly increased [3H]IP formation in a dose-dependent manner and the rate of [3H]IP formation mediated by carbachol stimulation was significantly accentuated in the presence of 10 microM vinconate. The enhancement of [3H]IP accumulation by vinconate was inhibited by approximately 50% in the presence of atropine (1-1000 microM), although up to 1 mM of phentolamine and ketanserin had no effect on the vinconate-induced increase of phosphatidylinositol turnover. Moreover, vinconate significantly accentuated 20 mM KCl-evoked stimulation of [3H]IP formation. Vinconate had no differential effect on the ratio of IP or inositol 1,4-biphosphate and inositol 1,4,5-triphosphate formations. These results suggest that vinconate may induce a facilitation of phosphatidylinositol turnover via the stimulation of muscarinic receptors and a facilitation of coupling between muscarinic receptors and GTP-binding protein. The presence of a direct stimulatory effect of vinconate on phosphatidylinositol turnover has also been suggested.

Effect of vinconate, an indolonaphthyridine derivative, on dopamine and serotonin concentrations in dialysate from the striatum of freely moving rats: brain microdialysis studies

The effect of (+/-)-methyl 3-ethyl-2,3,3a, 4-tetrahydro-1H-indolo[3,2,1-de][1,5]naphthyridine -6-carboxylate monohydrochloride (vinconate), an indolonaphthyridine derivative, on dopamine and serotonin concentrations in dialysate from the striatum of freely moving rats was examined by brain microdialysis. Twenty-minute samples collected were used to determine dopamine and serotonin by high-performance liquid chromatography in a single run. The basal extracellular levels of dopamine and serotonin were 41.12 +/- 5.04 and 10.41 +/- 1.71 (fmol/20 min), respectively. Dopamine concentrations in dialysate were significantly increased after a single treatment with vinconate (50-200 mg/kg p.o.). Tetrodotoxin (10 microM) added into the dialysis perfusate decreased dopamine concentrations in dialysate and vinconate had no effect on dopamine concentrations in dialysate when administered after tetrodotoxin. The vinconate-induced increase in dialysate dopamine concentrations was significantly reduced by scopolamine (1 microM) and N0434 (1 microM), respectively. Moreover, daily treatment with vinconate (25 mg/kg p.o.) for 7 days resulted in enhanced dopamine and serotonin concentrations in dialysate induced by subsequent vinconate treatment. These findings suggest that vinconate administered systemically can enhance dialysate dopamine concentrations and this effect may be related to the muscarinic receptor and the dopamine D2 receptor. The present findings also suggest that repeated treatment with vinconate may augment these effects of vinconate on dopamine and serotonin concentrations in dialysate from the brain.

Effect of vinconate on the extracellular levels of dopamine and its metabolites in the rat striatum: microdialysis studies

The effects of (+/-)-methyl-3-ethyl-2,3,3 alpha, 4-tetrahydro-1H- indolo[3,2,1-de][1,5]naphthyridine-6-carboxylate hydrochloride (vinconate), an indolonaphthyridine derivative, on the extracellular levels of dopamine and its metabolites in the rat striatum were examined using brain microdialysis. Single administration of vinconate (10, 100 mg/kg i.p.) increased the extracellular level of dopamine and its metabolites. This enhancing effect of vinconate was antagonized by scopolamine (10 microM), a muscarinic receptor antagonist, which was added to the perfusate from 30 min before vinconate treatment. These findings suggest that vinconate, even when systemically administered, enhances the endogenous release of dopamine in the striatum, probably via the stimulation of presynaptic muscarinic receptors.

Effects of vinconate on scopolamine-induced memory impairment in rhesus monkeys

Effects of vinconate on specifically impaired short-term memory were studied in rhesus monkeys. Monkeys were trained to perform for orange juice reinforcement under a matching-to-sample response procedure. In the procedure, monkeys had to choose one of two stimuli that had the same color as the sample stimulus. Half of a daily session consisted of simultaneous trials where the sample stimulus was present during the time of choice. The other half of the session consisted of delayed trials where the sample stimulus had been presented but withheld at the time of choice. After the repeated training, the matching-to-sample responses were established with the percentage of correct choice responses (CR%) in both types of trials exceeding 90%. The doses of scopolamine, intervals between administration of this drug and the start of test session, and delay times in delayed trials were adjusted from one monkey to another so that delayed matching-to-sample responses were impaired by scopolamine while simultaneous matching-to-sample responses were less impaired by this drug. Scopolamine (32 or 45 micrograms/kg, s.c.) decreased the CR% for delayed trials more markedly than the CR% for simultaneous trials in four monkeys. Intragastrically administered vinconate at 16 mg/kg attenuated the scopolamine-induced short-term memory impairment. These results suggested that vinconate possesses specific ameliorating action on memory impairment caused by hypofunction of the cholinergic system in the brain.

Effect of vinconate, an indolonaphthyridine derivative, on metabolism and function of cerebral cholinergic neurons in rat

Effects of (+/-)-methyl 3-ethyl-2,3,3a,4-tetrahydro-1H-indolo [3,2,1,-de] [1,5] naphthyridine-6-carboxylate hydrochloride (vinconate), an indolonaphthyridine derivative, on the metabolism and function of cerebral cholinergic neurons were investigated using male Wistar rats. Single administration of vinconate (5, 50 and 200 mg/kg) decreased acetylcholine content in the striatum but not those in the cerebral cortex and hippocampus. The same treatment with vinconate (5, 50 and 200 mg/kg, p.o.) had no effect on the activities of choline acetyltransferase and acetylcholinesterase in these brain areas. Although the addition of vinconate (10(-7) - 10(-4) M) had no effect on the high affinity uptake of [3H]choline into striatal slices, it induced a concentration-dependent increase of a KCl(2 x 10(-2) M)-evoked endogenous acetylcholine release. The addition of (-)-sulpiride (10(-8) - 10(-6) M), a dopamine D2 receptor antagonist, also accentuated the KCl(2 x 10(-2) M)-evoked endogenous acetylcholine release form striatal slices. Furthermore, it was found that this (-)-sulpiride (10(-7) M)-induced increase of endogenous acetylcholine release was further augmented by the addition of vinconate (10(-5) M). These results suggest that vinconate may enhance the release of endogenous acetylcholine via the modulation of presynaptic dopamine heteroreceptor in the striatum.